Evidence map›Paper›PMID 42254409›Full record

ArticleFrontiers in medicine2026

Successful management of severe

Haobo Kong, Jingjing Pan, Jialin Liu, Min Liang, Liu Liu, Hua Niu, Ye Li

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haobo Kong *Department of Respiratory Intensive Care Unit, Anhui Chest Hospital, Hefei, Anhui, China.
Jingjing Pan *Department of Respiratory Intensive Care Unit, Anhui Chest Hospital, Hefei, Anhui, China.
Jialin Liu *Department of Pulmonary and Critical Care Medicine, Anhui Chest Hospital, Hefei, Anhui, China.
Min LiangDepartment of Tuberculosis, Anhui Chest Hospital, Hefei, Anhui, China.
Liu LiuOperating Room of Anhui Chest Hospital, Hefei, Anhui, China.
Hua NiuDepartment of Pulmonary and Critical Care Medicine, Anhui Chest Hospital, Hefei, Anhui, China.
Ye LiDepartment of Tuberculosis, Anhui Chest Hospital, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors (ICIs) have improved survival in extensive-stage small-cell lung cancer (SCLC) but may cause checkpoint inhibitor pneumonitis (CIP). Management of CIP often requires prolonged high-dose corticosteroids, leading to profound immunosuppression and increased risk of opportunistic infections. Among these, Case presentation: A 69-year-old HIV-negative man with extensive-stage SCLC received four cycles of etoposide-platinum chemotherapy plus adebrelimab. Subsequently, CIP developed and required prolonged high-dose methylprednisolone therapy. He was transferred to our hospital for progressive dyspnea. Evaluation showed severe hypoxemia (PaO₂/FiO₂ 185 mmHg) and markedly elevated serum 1,3- Conclusion: Severe PJP should be considered in non-HIV patients receiving corticosteroids for CIP. mNGS enabled rapid pathogen identification and targeted therapy. Comprehensive respiratory support, including optimized mechanical ventilation and inhaled nitric oxide, may be valuable in managing life-threatening opportunistic infections in immunosuppressed patients.

Indexed as

immunosuppressioninhaled nitric oxidemechanical ventilationmetagenomic next-generation sequencingPneumocystis jirovecii pneumonia

Identifiers

PMID42254409
PMCPMC13237688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.